(Q46577786)
English
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
scientific article published on 7 November 2013
Statements
1 reference
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses (English)
1 reference
Ulrike Gnad-Vogt
1 reference
Karl-Josef Kallen
1 reference
Birgit Scheel
1 reference
Gerd Rippin
1 reference
Arnulf Stenzl
1 reference
7 November 2013
1 reference
1
1 reference
Suppl 1
1 reference
P219-P219
1 reference
1 November 2013
1 reference
Identifiers
1 reference